| 2020-GHOS-68848 | |
| Researchers at Purdue University have developed an efficient method to synthesize an optically pure sub-unit bis-THF, a key structure for producing the HIV-1 drug Darunavir. Darunavir is the most recent FDA approved HIV-1 protease inhibitor drug for the treatment of patients with HIV-1 infection and AIDS. It is potent against highly multidrug resistant HIV-1 variants and has become the front-line therapy for the treatment of HIV/ AIDS. Current methods of Darunavir synthesis often involve numerous complex steps and the resulting bis-THF may not be optically pure. Further, these methods frequently have high cost associated with the starting materials and reagents and the synthesis time is often lengthy. Researchers at Purdue University have developed a method that uses optically active sugars to synthesize optically pure bis-THF. This inexpensive and efficient method is beneficial for scaling up the synthesis of Darunavir. Technology Validation: Reactions were carried out under an atmosphere of argon. Purification was performed by flash chromatography. Analytical thin layer chromatography, NMR spectroscopy, and mass spectroscopy were conducted on samples for analysis. Advantages - Increased synthesis efficiency - Low cost - Easily scaled up - Produces a higher quantity of optically pure ligand Applications - Treatment of HIV/Aids - Drug manufacture (HIV/AIDS drug products) |
|
|
|
|
Feb 8, 2023
NATL-Patent
United States
(None)
(None)
Jun 11, 2021
PCT-Gov. Funding
WO
(None)
(None)
Jun 11, 2021
NATL-Patent
Europe
(None)
(None)
Aug 11, 2020
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
